Page 195 - 18F-FDG PET as biomarker in aggressive lymphoma; technical and clinical validation

R-CHOP with lenalidomide in MYC+ LBCL
of an interim PET-CT scan as interpreted with the current standard criteria to identify primary refractory cases treated with R2CHOP.
In this prospective trial for newly diagnosed MYC+ LBCL patients, we found that administering R2CHOP was safe, and yielded comparable CMR and survival rates as in studies applying intensive chemotherapy regimens. Moreover, R2CHOP can be delivered on an outpatient basis in contrast to Burkitt schemes and is easier to deliver than DA-EPOCH-R, since it does not require placement of a central line. These findings offer new prospects for MYC+ LBCL patients and warrant comparison in prospective randomized trials.
Acknowledgements
The authors wish to acknowledge: the trial managers and central data managers of the study (N. Lamers and A. Elsinghorst, R. Sewsaran and H. Hofwegen), HOVON data Center in Rotterdam; Dr Staudt’s Laboratory at NCI/NIH Bethesda, MD, USA, for online analysis of Lymph2Cx raw data for COO characterization; and the DSMB members M. Jerkeman, K. Dunleavy and E. van Werkhoven for their advice following the interim analysis.
Funding
This work was supported by Celgene who funded the research, provided lenalidomide free of charge, approved the original protocol and all amendments as written, but had no role in either the design of the study, the collection, analysis, and interpretation of the data, or the preparation of the manuscript. The Dutch Cancer Society provided funding for the screening program and the clinical trial.
193
7